Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 19/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7129708 | 1.00 | PTAFR (0.78) | PTAFR | |
| SCHEMBL7662186 | 1.00 | PTAFR (0.78) | PTAFR | |
| SCHEMBL9689979 | 0.94 | PTAFR (0.89) | PTAFR | |
| SCHEMBL9689973 | 0.94 | PTAFR (0.89) | PTAFR | |
| SCHEMBL9689982 | 0.94 | PTAFR (0.89) | PTAFR | |
| SCHEMBL9859944 | 0.93 | PTAFR (0.86) | PTAFR | |
| SCHEMBL9859486 | 0.93 | PTAFR (0.86) | PTAFR | |
| SCHEMBL9859932 | 0.93 | PTAFR (0.86) | PTAFR | |
| SCHEMBL10459680 | 0.92 | PTAFR (0.72) | PTAFR | |
| SCHEMBL7663731 | 0.90 | PTAFR (0.86) | PTAFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0749306-A4 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED INC (US) | 1997-04-16 | — | — | EP | claimed |
| EP-0749306-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1996-12-27 | — | — | EP | claimed |
| US-5463083-A | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders | CYTOMED, INC. (US) | 1995-10-31 | — | — | US | claimed |
| WO-1995018610-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1995-07-13 | — | — | WO | claimed |
| US-20020128491-A1 | Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans | RAO ALLA VENKATA RAMA (IN) | 2002-09-12 | — | — | US | disclosed |
| US-6420392-B1 | PAF RECEPTOR ANTAGONISTS AND/OR BY INHIBITING THE ENZYME 5-LIPOXYGENASE. | MILLENNIUM PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| US-6403814-B1 | REACTING WITH GRIGNARD REAGENT COMPOUND HAVING CARBON SUBSTITUTED BY ACETYLENE GROUP, ARYL GROUP AND HYDROXYL GROUP, HYDROGENATING ACETYLENE MOIETY OF REACTION PRODUCT, CYCLIZING TO PROVIDE DI-ARYL TETRAHYDROFURAN | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-5741809-A | Compounds and methods for the treatment of cardiovascular inflammatory and immune disorders | CYTOMED, INC. (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0749306-A4 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED INC (US) | 1997-04-16 | — | — | EP | disclosed |
| EP-0749306-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5463083-A | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders | CYTOMED, INC. (US) | 1995-10-31 | — | — | US | disclosed |
| WO-1995018610-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128491-A1 | Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans | TPMT, TPI1, GTF2I | PTAFR 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.